Education
About Us
Working with TipRanks
Follow Us
Newron Pharmaceuticals SpA (NWPHF)
:NWPHF
RESEARCH TOOLSreports
Total Valuation
Newron Pharmaceuticals SpA has a market cap or net worth of $176.00M. The enterprise value is $60.17M.
Market Cap$176.00M
Enterprise Value$60.17M
Share Statistics
Newron Pharmaceuticals SpA has 19,960,995 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding19,960,995
Owned by Insiders―
Owned by Institutions0.05%
Financial Efficiency
Newron Pharmaceuticals SpA’s return on equity (ROE) is 10.87 and return on invested capital (ROIC) is 35.92%.
Return on Equity (ROE)10.87
Return on Assets (ROA)0.25
Return on Invested Capital (ROIC)35.92%
Return on Capital Employed (ROCE)0.65
Revenue Per Employee2.34M
Profits Per Employee972.45K
Employee Count22
Asset Turnover0.80
Inventory Turnover0.00
Valuation Ratios
The current PE Ratio of Newron Pharmaceuticals SpA is 11.15. Newron Pharmaceuticals SpA’s PEG ratio is -0.10.
PE Ratio11.15
PS Ratio0.00
PB Ratio-1.99
Price to Fair Value121.21
Price to FCF-2.51
Price to Operating Cash Flow-2.52
PEG Ratio-0.10
Income Statement
In the last 12 months, Newron Pharmaceuticals SpA had revenue of 51.39M and earned 15.84M in profits. Earnings per share was 0.85.
Revenue51.39M
Gross Profit51.39M
Operating Income26.17M
Pretax Income21.39M
Net Income15.84M
EBITDA25.94M
Earnings Per Share (EPS)0.85
Cash Flow
In the last 12 months, operating cash flow was -17.61M and capital expenditures -13.00K, giving a free cash flow of -17.63M billion.
Operating Cash Flow-17.61M
Free Cash Flow-17.63M
Free Cash Flow per Share-0.88
Dividends & Yields
Newron Pharmaceuticals SpA pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta0.42
52-Week Price Change-14.13%
50-Day Moving Average9.36
200-Day Moving Average9.35
Relative Strength Index (RSI)38.97
Average Volume (3m)0.00
Important Dates
Newron Pharmaceuticals SpA upcoming earnings date is Sep 16, 2025, TBA Not Confirmed.
Last Earnings DateApr 1, 2025
Next Earnings DateSep 16, 2025
Ex-Dividend Date―
Financial Position
Newron Pharmaceuticals SpA as a current ratio of 2.60, with Debt / Equity ratio of -325.46%
Current Ratio2.60
Quick Ratio2.60
Debt to Market Cap0.28
Net Debt to EBITDA1.68
Interest Coverage Ratio6.01
Taxes
In the past 12 months, Newron Pharmaceuticals SpA has paid 5.55M in taxes.
Income Tax5.55M
Effective Tax Rate0.26
Enterprise Valuation
Newron Pharmaceuticals SpA EV to EBITDA ratio is 8.49, with an EV/FCF ratio of -12.50.
EV to Sales4.29
EV to EBITDA8.49
EV to Free Cash Flow-12.50
EV to Operating Cash Flow-12.50
Balance Sheet
Newron Pharmaceuticals SpA has $9.83M in cash and marketable securities with €50.47M in debt, giving a net cash position of $40.64M billion.
Cash & Marketable Securities$9.83M
Total Debt€50.47M
Net Cash$40.64M
Net Cash Per Share$2.04
Tangible Book Value Per Share$0.08
Margins
Gross margin is 100.00%, with operating margin of 50.93%, and net profit margin of 30.83%.
Gross Margin100.00%
Operating Margin50.93%
Pretax Margin41.63%
Net Profit Margin30.83%
EBITDA Margin50.47%
EBIT Margin50.10%
Analyst Forecast
The average price target for Newron Pharmaceuticals SpA is ―, which is 11.43% higher than the current price. The consensus rating is ―
Price Target―
Price Target Upside―
Analyst Consensus―
Analyst Count0
Revenue Growth Forecast―
EPS Growth Forecast―